The DOI matches its Crossref record; 64 of the 64 references it cites were found in a registry or an index.
Positron emission tomographic imaging of the dopamine transporter with 11C‐WIN 35,428 reveals marked declines in mild Parkinson's disease
Abstract
Parkinson's Disease (PD) is characterized by a selective loss of nigrostriatal dopaminergic neurons that results in a marked reduction of dopaminergic nerve terminals in the striatum. Recently, 11 C‐WIN 35,428, a cocaine analogue that specifically labels the dopamine transporter, was developed and can be used to label dopaminergic nerve terminals in vivo by positron emission tomography. In healthy control subjects, binding of 11 C‐WIN 35,428 is highest in the striatum. In addition, 2 symmetrical focal areas of low binding were observed in the midbrain. The cerebellum functioned as an appropriate region for nonspecific binding. The binding of 11 C‐WIN 35,428 in patients with PD (Hoehn‐Yahr II) was compared with that in healthy control subjects by using the (region‐cerebellum)/cerebellum ratio for data acquired 34 to 82 minutes after injection. In control subjects, this ratio varied, at approximately 2, in the striatum. In patients with PD, binding in the posterior putamen was reduced by 78%, whereas the anterior putamen and the caudate nucleus showed a reduction of 59 and 39%, respectively. The reduction in 11 C‐WIN 35,428 binding was highest in the midbrain (84%). The high specific/nonspecific binding ratio and the pronounced reduction in binding in mild PD may permit detection of even earlier stages of PD or presymptomatic individuals with dopaminergic cell loss.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Bernheimer, H., Birkmayer, W., Hornykiewicz, O., Jellinger, K., & Seitelberger, F. (1973) · Journal of the Neurological Sciences · doi:10.1016/0022-510x(73)90175-5 · Cited by 2,651
Uneven Pattern of Dopamine Loss in the Striatum of Patients with Idiopathic Parkinson's Disease
Kish, S. J., Shannak, K., & Hornykiewicz, O. (1988) · New England Journal of Medicine · doi:10.1056/nejm198804073181402 · Cited by 1,953
Effects of Tocopherol and Deprenyl on the Progression of Disability in Early Parkinson's Disease
(1993) · New England Journal of Medicine · doi:10.1056/nejm199301213280305 · Cited by 1,221
The dopamine hypothesis of the reinforcing properties of cocaine
Kuhar, M. J., Ritz, M. C., & Boja, J. W. (1991) · Trends in Neurosciences · doi:10.1016/0166-2236(91)90141-g · Cited by 987
Central Catecholamine Neuron Systems: Anatomy and Physiology of the Dopamine Systems
Moore, R. Y., & Bloom, F. E. (1978) · Annual Review of Neuroscience · doi:10.1146/annurev.ne.01.030178.001021 · Cited by 926
Effect of Deprenyl on the Progression of Disability in Early Parkinson's Disease
The Parkinson Study Group* (1989) · New England Journal of Medicine · doi:10.1056/nejm198911163212004 · Cited by 917
Biochemical pathophysiology of Parkinson's disease.
Hornykiewicz, O., & Kish, S. J. (1987) · PubMed · Cited by 849
Müller-Gärtner, H. W., Links, J. M., Prince, J. L., Bryan, R. N., McVeigh, E., Leal, J. P., Davatzikos, C., & Frost, J. J. (1992) · Journal of Cerebral Blood Flow & Metabolism · doi:10.1038/jcbfm.1992.81 · Cited by 756
Self-citationWong, D. F., Wagner, H. N., Dannals, R. F., Links, J. M., Frost, J. J., Ravert, H. T., Wilson, A. A., Rosenbaum, A. E., Gjedde, A., Douglass, K. H., et al. (1984) · Science · doi:10.1126/science.6334363 · Cited by 697
Self-citationThe Effect of Deprenyl (Selegiline) on the Natural History of Parkinson's Disease
Tetrud, J. W., & Langston, J. W. (1989) · Science · doi:10.1126/science.2502843 · Cited by 638
Brooks, D. J., Ibanez, V., Sawle, G. V., Quinn, N., Lees, A. J., Mathias, C. J., Bannister, R., Marsden, C. D., & Frackowiak, R. S. J. (1990) · Annals of Neurology · doi:10.1002/ana.410280412 · Cited by 626
A Stereotactic Method of Anatomical Localization for Positron Emission Tomography
Fox, P. T., Perlmutter, J. S., & Raichle, M. E. (1985) · Journal of Computer Assisted Tomography · doi:10.1097/00004728-198501000-00025 · Cited by 572
Heikkila, R. E., Orlansky, H., & Cohen, G. (1975) · Biochemical Pharmacology · doi:10.1016/0006-2952(75)90152-5 · Cited by 468
Midbrain dopaminergic cell loss in parkinson's disease: Computer visualization
German, D. C., Manaye, K., Smith, W. K., Woodward, D. J., & Saper, C. B. (1989) · Annals of Neurology · doi:10.1002/ana.410260403 · Cited by 396
Brooks, D. J., Ibanez, V., Sawle, G. V., Playford, E. D., Quinn, N., Mathias, C. J., Lees, A. J., Marsden, C. D., Bannister, R., & Frackowiak, R. S. J. (1992) · Annals of Neurology · doi:10.1002/ana.410310209 · Cited by 396
Leenders, K. L., Salmon, E. P., Tyrrell, P., Perani, D., Brooks, D. J., Sager, H., Jones, T., Marsden, C. D., & Frackowiak, R. S. J. (1990) · Archives of Neurology · doi:10.1001/archneur.1990.00530120034007 · Cited by 376
Dementia in Parkinson's disease is related to neuronal loss in the medial substantia nigra
Rinne, J. O., Mlic, J. R., Paljärvi, L., & Rinne, U. K. (1989) · Annals of Neurology · doi:10.1002/ana.410260107 · Cited by 331
Mapping cocaine binding sites in human and baboon brain in vivo
Fowler, J. S., Volkow, N. D., Wolf, A. P., Dewey, S. L., Schlyer, D. J., MacGregor, R. R., Hitzemann, R., Logan, J., Bendriem, B., Gatley, S. J., et al. (1989) · Synapse · doi:10.1002/syn.890040412 · Cited by 290
Nigrostriatal function in humans studied with positron emission tomography
Martin, W. R. W., Palmer, M. R., Patlak, C. S., & Calne, D. B. (1989) · Annals of Neurology · doi:10.1002/ana.410260407 · Cited by 282
BROOKS, D. J., SALMON, E. P., MATHIAS, C. J., QUINN, N., LEENDERS, K. L., BANNISTER, R., MARSDEN, C. D., & FRACKOWIAK, R. S. J. (1990) · Brain · doi:10.1093/brain/113.5.1539 · Cited by 256
Neumeyer, J. L., Wang, S., Milius, R. A., Baldwin, R. M., Zea-Ponce, Y., Hoffer, P. B., Sybirska, E., Al-Tikriti, M., & Charney, D. S. (1991) · Journal of Medicinal Chemistry · doi:10.1021/jm00114a027 · Cited by 239
Isolated tremor and disruption of the nigrostriatal dopaminergic system: An 18 F‐dopa PET study
Brooks, D. J., Playford, E. D., Ibanez, V., Sawle, G. V., Thompson, P. D., Findley, L. J., & Marsden, C. D. (1992) · Neurology · doi:10.1212/wnl.42.8.1554 · Cited by 232
Church, W. H., Justice, J. B., & Byrd, L. D. (1987) · European Journal of Pharmacology · doi:10.1016/0014-2999(87)90592-9 · Cited by 226
Hurd, Y. L., & Ungerstedt, U. (1989) · Synapse · doi:10.1002/syn.890030107 · Cited by 215
High‐affinity binding of [125I]RTI‐55 to dopamine and serotonin transporters in rat brain
Boja, J. W., Mitchell, W. M., Patel, A., Kopajtic, T. A., Carroll, F. I., Lewin, A. H., Abraham, P., & Kuhar, M. J. (1992) · Synapse · doi:10.1002/syn.890120104 · Cited by 212
[3H]spiperone binding, dopamine and HVA concentrations in Parkinson's disease and supranuclear palsy
Bokobza, B., Ruberg, M., Scatton, B., Javoy-Agid, F., & Agid, Y. (1984) · European Journal of Pharmacology · doi:10.1016/0014-2999(84)90238-3 · Cited by 210
Sawle, G. V., Bloomfield, P. M., Ourklund, A. B., Brooks, D. J., Brundin, P., Leenders, K. L., Lindvall, O., Marsden, C. D., Rehncrona, S., Widner, H., et al. (1992) · Annals of Neurology · doi:10.1002/ana.410310207 · Cited by 201
Parkinson's disease in twins studied with 18 F‐dopa and positron emission tomography
Burn, D. J., Mark, M. H., Playford, E. D., Maraganore, D. M., Zimmerman, T. R., Duvoisin, R. C., Harding, A. E., Marsden, C. D., & Brooks, D. J. (1992) · Neurology · doi:10.1212/wnl.42.10.1894 · Cited by 197
Parkinson's disease and dementia: Norepinephrine and dopamine in locus ceruleus
Cash, R., Dennis, T., L'Heureux, R., Raisman, R., Javoy-Agid, F., & Scatton, B. (1987) · Neurology · doi:10.1212/wnl.37.1.42 · Cited by 196
Frost, J. J., Douglass, K. H., Mayberg, H. S., Dannals, R. F., Links, J. M., Wilson, A. A., Ravert, H. T., Crozier, W. C., & Wagner, H. N. (1989) · Journal of Cerebral Blood Flow & Metabolism · doi:10.1038/jcbfm.1989.59 · Cited by 194
Self-citationDopamine deficiency in the cerebral cortex in Parkinson disease
Scatton, B., Rouquier, L., Javoy-Agid, F., & Agid, Y. (1982) · Neurology · doi:10.1212/wnl.32.9.1039 · Cited by 183
Parkinson's Disease: Activity of L-Dopa Decarboxylase in Discrete Brain Regions
Lloyd, K., & Hornykiewicz, O. (1970) · Science · doi:10.1126/science.170.3963.1212 · Cited by 176
Wong, D. F., Yung, B., Dannals, R. F., Shaya, E. K., Ravert, H. T., Chen, C. A., Chan, B., Folio, T., Scheffel, U., Ricaurte, G. A., et al. (1993) · Synapse · doi:10.1002/syn.890150205 · Cited by 174
Self-citationMayberg, H. S., Sadzot, B., Meltzer, C. C., Fisher, R. S., Lesser, R. P., Dannals, R. F., Lever, J. R., Wilson, A. A., Ravert, H. T., Wagner, H. N., et al. (1991) · Annals of Neurology · doi:10.1002/ana.410300103 · Cited by 170
Self-citationDopa decarboxylase activity of the living human brain.
Gjedde, A., Reith, J., Dyve, S., Léger, G., Guttman, M., Diksic, M., Evans, A., & Kuwabara, H. (1991) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.88.7.2721 · Cited by 170
Baron, J. C., Frackowiak, R. S. J., Herholz, K., Jones, T., Lammertsma, A. A., Mazoyer, B., & Wienhard, K. (1989) · Journal of Cerebral Blood Flow & Metabolism · doi:10.1038/jcbfm.1989.105 · Cited by 168
Striatal function in normal aging: Implications for Parkinson's disease
Sawle, G. V., Colebatch, J. G., Shah, A., Brooks, D. J., Marsden, C. D., & Frackowiak, R. S. J. (1990) · Annals of Neurology · doi:10.1002/ana.410280611 · Cited by 159
Dopamine receptor interactions: some implications for the treatment of Parkinson's disease
Robertson, H. A. (1992) · Trends in Neurosciences · doi:10.1016/0166-2236(92)90034-6 · Cited by 154
Rinne, U. K., Laihinen, A., Rinne, J. O., Någren, K., Bergman, J., & Ruotsalainen, U. (1990) · Movement Disorders · doi:10.1002/mds.870050114 · Cited by 150
Central Dopaminergic Pathways in Hemiparkinsonism Examined by Positron Emission Tomography
Garnett, E. S., Nahmias, C., & Firnau, G. (1984) · Canadian Journal of Neurological Sciences / Journal Canadien des Sciences Neurologiques · doi:10.1017/s0317167100046369 · Cited by 145
Aquilonius, S., Bertröm, K., Eckernas, S., Hartvig, P., Leenders, K. L., Lundquist, H., Antoni, G., Gee, A. D., Rimland, A., Uhlin, J., et al. (1987) · Acta Neurologica Scandinavica · doi:10.1111/j.1600-0404.1987.tb03582.x · Cited by 144
Goto, S., Hirano, A., & Matsumoto, S. (1989) · Annals of Neurology · doi:10.1002/ana.410260613 · Cited by 138
Parkinson's Disease: Neurobehavioral Aspects
Huber, S. J., & Cummings, J. L. (1992) · Medical Entomology and Zoology · Cited by 128
[125I]RTI-55: a potent ligand for dopamine transporters
Boja, J. W., Patel, A. P., Carroll, F. I., Rahman, M. A., Abraham, P., Lewin, A. H., Kopajtic, T. A., & Kuhar, M. J. (1991) · European Journal of Pharmacology · doi:10.1016/0014-2999(91)90137-f · Cited by 120
6-[ 18 F]fluoro-l-DOPA Metabolism in Living Human Brain: A Comparison of Six Analytical Methods
Hoshi, H., Kuwabara, H., Léger, G. C., Cumming, P. D., Guttman, M., & GJEDDE, A. H. (1993) · Journal of Cerebral Blood Flow & Metabolism · doi:10.1038/jcbfm.1993.8 · Cited by 110
Kuwabara, H., Cumming, P. D., Reith, J., Léger, G. C., Dikšić, M., Evans, A. C., & GJEDDE, A. H. (1993) · Journal of Cerebral Blood Flow & Metabolism · doi:10.1038/jcbfm.1993.7 · Cited by 104
Sadzot, B., Price, J. C., Mayberg, H. S., Douglass, K. H., Dannals, R. F., Lever, J. R., Ravert, H. T., Wilson, A. A., Wagner, H. N., Feldman, M. A., et al. (1991) · Journal of Cerebral Blood Flow & Metabolism · doi:10.1038/jcbfm.1991.52 · Cited by 95
Self-citationHolthoff‐Detto, V., Koeppe, R. A., Frey, K. A., Paradise, A. H., & Kuhl, D. E. (1991) · Journal of Cerebral Blood Flow & Metabolism · doi:10.1038/jcbfm.1991.131 · Cited by 93
Janowsky, A. J., Vocci, F. J., Berger, P. A., Angel, I., Zelnik, N., Kleinman, J. E., Skolnick, P., & Paul, S. M. (1987) · Journal of Neurochemistry · doi:10.1111/j.1471-4159.1987.tb02908.x · Cited by 88
Shaya, E. K., Scheffel, U., Dannals, R. F., Ricaurte, G. A., Carroll, F. I., Wagner, H. N., Kuhar, M. J., & Wong, D. F. (1992) · Synapse · doi:10.1002/syn.890100210 · Cited by 85
Self-citationMaloteaux, J., Vanisberg, M.-A., Laterre, C. E., et al. (1988) · European Journal of Pharmacology · doi:10.1016/0014-2999(88)90278-6 · Cited by 85
Detection of preclinical Parkinson's disease with PET
Brooks, D. J. (1991) · Neurology · doi:10.1212/wnl.41.5_suppl_2.24 · Cited by 83
Price, J. C., Mayberg, H. S., Dannals, R. F., Wilson, A. A., Ravert, H. T., Sadzot, B., Rattner, Z., Kimball, A. W., Feldman, M. A., & Frost, J. J. (1993) · Journal of Cerebral Blood Flow & Metabolism · doi:10.1038/jcbfm.1993.84 · Cited by 78
Self-citationDopamine Uptake Sites and Dopamine Receptors in Parkinson’s Disease and Schizophrenia
Pearce, R. K. B., Seeman, P. M., Jellinger, K., & Tourtellotte, W. W. (2008) · European Neurology · doi:10.1159/000117168 · Cited by 72
Quantitative autoradiography of 3H-nomifensine binding sites in rat brain
Scatton, B., Dubois, A., Dubocovich, M. L., Zahniser, N. R., & Fage, D. (1985) · Life Sciences · doi:10.1016/0024-3205(85)90204-8 · Cited by 69
Cline, E. J., Scheffel, U., Boja, J. W., et al. (1992) · Synapse · doi:10.1002/syn.890120105 · Cited by 67
Mapping dopamine receptors in the human brain
Palacios, J. M., Camps, M., Cortés, R., & Probst, A. (1988) · Springer eBooks · doi:10.1007/978-3-7091-8954-2_20 · Cited by 60
Anatomical Localization for PET Using MR Imaging
MELTZER, C. C., Bryan, R. N., Holcomb, H. H., Kimball, A. W., Mayberg, H. S., Sadzot, B., Leal, J. P., Wagner, H. N., & Frost, J. J. (1990) · Journal of Computer Assisted Tomography · doi:10.1097/00004728-199005000-00019 · Cited by 58
Self-citationQuantitative Imaging : Neuroreceptors Neurotransmitters and Enzymes
Wagner, H. N., & Frost, J. J. (1990) · Medical Entomology and Zoology · Cited by 54
Self-citationHIRAI, M., Kitamura, N., Hashimoto, T., NAKAI, T., Mita, T., Shirakawa, O., Yamadori, T., Amano, T., NOGUCHI-KUNO, S. A., & Tanaka, C. (1988) · The Japanese Journal of Pharmacology · doi:10.1254/jjp.47.237 · Cited by 54
Dannals, R. F., Neumeyer, J. L., Milius, R. A., Ravert, H. T., Wilson, A. A., & Wagner, H. N. (1993) · Journal of Labelled Compounds and Radiopharmaceuticals · doi:10.1002/jlcr.2580330209 · Cited by 51
Self-citationDopamine transporter imaging with novel, selective cocaine analogs
Scheffel, U., Dannais, R. F., Wong, D. F., et al. (1992) · Neuroreport · doi:10.1097/00001756-199211000-00005 · Cited by 29
d'Argy, R., Gillberg, P., Stålnacke, C.-G., et al. (1988) · Neuroscience Letters · doi:10.1016/0304-3940(88)90583-6 · Cited by 23
Parkinson’s Disease: Neurotransmitter and Neurotoxin Receptors and Their Genes
Uhl, G. R. (2008) · European Neurology · doi:10.1159/000117170 · Cited by 22
Cited by
The substantia nigra of the human brain
Damier, P., Hirsch, E. C., Agid, Y., & Graybiel, A. M. (1999) · Brain · doi:10.1093/brain/122.8.1437 · Cited by 1,756
Kapur, S., Zipursky, R., Jones, C., Remington, G., & Houle, S. (2000) · American Journal of Psychiatry · doi:10.1176/appi.ajp.157.4.514 · Cited by 1,090
Association of Dopamine Transporter Reduction With Psychomotor Impairment in Methamphetamine Abusers
Volkow, N. D., Chang, L., Wang, G.-J., Fowler, J. S., Leonido-Yee, M., Franceschi, D., Sedler, M. J., Gatley, S. J., Hitzemann, R., Ding, Y.-S., et al. (2001) · American Journal of Psychiatry · doi:10.1176/appi.ajp.158.3.377 · Cited by 984
Core assessment program for surgical interventional therapies in Parkinson's disease (CAPSIT-PD)
Defer, G.-L., Widner, H., Mari�, R.-M., R�my, P., Levivier, M., & Conference Participants: Conference Participants: G. L. Defer, M. (. (1999) · Movement Disorders · doi:10.1002/1531-8257(199907)14:4<572::aid-mds1005>3.0.co;2-c · Cited by 865
Microglial activation and dopamine terminal loss in early Parkinson's disease
Ouchi, Y., Yoshikawa, E., Sekine, Y., Futatsubashi, M., Kanno, T., Ogusu, T., & Torizuka, T. (2005) · Annals of Neurology · doi:10.1002/ana.20338 · Cited by 843
Metadata
- Authors
- Frost, J. J., Rosier, A. J., Reich, S. G., Smith, J. S., Ehlers, M. D., Snyder, S. H., Ravert, H. T., & Dannals, R. F.
- Venue
- Annals of Neurology
- Publisher
- Wiley
- Published
- 1993-09
- Volume
- 34
- Issue
- 3
- Pages
- 423-431
- ISSN
- 0364-5134 (ISSN-L)
- 1531-8249
- OpenAlex
- W2060626983
- Cited by
- 320
- References
- 64
- FWCI
- 14.04
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.